Skip to main content

TCR2 Therapeutics Inc.

TCRRDelisted Jun 1, 2023
Industry
Biological Products, (No Diagnostic Substances)
SEC CIK
0001750019

TCR2 Therapeutics Inc. was delisted on Jun 1, 2023; its insiders filed their last Form 4 on Feb 14, 2024; 59 institutions reported holding it in 13F filings for Q1 2023, worth $31.5M in total; no superinvestor held it.

Q4 2022 vs. Q3 2022

How the institutions holding TCR2 Therapeutics Inc. changed between Q3 2022 and Q4 2022.

All holders in Q4 2022All holders in Q3 2022

13F holders of TCRR: Q3 2022 compared with Q4 2022
MeasureQ3 2022Q4 2022Change
Holders8163−18
Shares25.0M21.2M−3.85M (−15.4%)
Value$45.1M$21.2M−$23.9M (−53.0%)

New holders (5)

Institutions that held TCR2 Therapeutics Inc. at the end of Q4 2022 but not at the end of Q3 2022.

Institutions new to TCRR in Q4 2022
InstitutionSharesValue% of portfolio
Commonwealth Equity Services, LLC22,473$22.0K0.00%
Virtu Financial LLC19,204$19.0K0.00%
HRT Financial LP12,864$12.0K0.00%
Belpointe Asset Management LLC2,147$2.14K0.00%
GWM Advisors LLC47$470.00%

Sold out (23)

Institutions that held TCR2 Therapeutics Inc. at the end of Q3 2022 and filed for Q4 2022 without it.